![](https://investorshub.advfn.com/uicon/48355.png?cb=1551739062)
Tuesday, July 05, 2022 4:57:07 PM
4:01 pm ET July 5, 2022 (Globe Newswire) Print
EQNX::TICKER_START (NASDAQ:AMTI), EQNX::TICKER_END Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naive patients with moderate-to-severe ulcerative colitis. The company will issue a premarket press release and host a live webcasted conference call on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT).
Conference Call & Webcast Information
To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast will be available on the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.
About Applied Molecular Transport Inc.
AMT is a clinical-stage biopharmaceutical company developing novel oral biologic product candidates, by leveraging its technology platform to design biologic product candidates in patient friendly oral dosage forms. AMT's product candidates are designed to precisely target the relevant pathophysiology of disease. AMT's proprietary technology platform is incorporated in its product candidates, exploiting existing natural cellular trafficking pathways to drive the active transport of diverse therapeutic modalities across the IE barrier. Active transport is an efficient mechanism that utilizes the cell's own machinery to transport materials across the IE barrier.
AMT's headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.
Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com
Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
https://ml.globenewswire.com/media/b117aa22-72cd-4100-86b2-5ef991192c9c/small/amt-cmyk-blue-80-60-8-0-logo-01-jpg.jpg
https://ml.globenewswire.com/media/b117aa22-72cd-4100-86b2-5ef991192c9c/small/amt-cmyk-blue-80-60-8-0-logo-
New York Yankees and Duke Basketball
Recent AMTI News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 01/09/2024 11:12:27 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/03/2024 05:15:07 AM
- Form POSASR - Post-effective Amendment to an automatic shelf registration statement • Edgar (US Regulatory) • 01/02/2024 02:15:36 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/02/2024 02:14:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 10:39:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 10:36:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 10:32:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 10:31:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 10:28:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 10:26:34 PM
- Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc. • Business Wire • 12/27/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 08:49:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 10:27:27 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/15/2023 09:06:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 09:05:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 09:52:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 09:47:25 PM
- Form DEFM14A - Definitive proxy statement relating to merger or acquisition • Edgar (US Regulatory) • 11/21/2023 02:16:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/16/2023 10:38:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:08:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:04:33 PM
- Applied Molecular Transport Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/09/2023 09:01:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM